Biotech & Pharma

STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a 'novel class' beyond it

alinemati1983-6987Apr 21

26 sec read16 views0 listens

Revolution Medicines presented promising clinical trial data for daraxonrasib in advanced pancreatic cancer and introduced RM-055, a novel class of catalytic inhibitors. This development matters as it advances targeted therapies beyond current RAS-inhibiting drugs, offering new treatment avenues for oncologists and biotech developers. Watch for further clinical trials to validate the efficacy and safety of RM-055 in human patients.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

alinemati1983-6987BlogUI.author_articles

BlogUI.view_profile

You Might Like

Biotech & Pharma11 hours ago23 sec read

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Aprea Therapeutics is accelerating enrollment in its Phase I trial of APR-1051, a WEE1 kinase inhibitor, after observing early signs of clinical activity. This expansion aims to gather more data on the drug's efficacy and safety, particularly for pat...

Ali Nemati

Biotech & Pharma11 hours ago29 sec read

The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates

Cindy Cheng, PhD, will discuss the development of dual-payload antibody-drug conjugates (dp-ADCs) to enhance efficacy and overcome drug resistance in cancer treatments. This innovation is crucial for biotech and pharma developers aiming to improve th...

Ali Nemati

Biotech & Pharma1 day ago24 sec read

Ancient Peptides Resurrected from Lactoferrin's Evolutionary Past Could Point to New Antibiotics

University of Oregon biologists have resurrected ancient lactoferrin peptides up to 160 million years old, which exhibit potent antimicrobial properties against drug-resistant bacteria. This discovery could provide new avenues for developing effectiv...

Ali Nemati